WE AIM TO DEVELOP INNOVATIVE THERAPIES THAT TARGET HIGH UNMET MEDICAL NEEDS IN ONCOLOGY AND BACTERIAL INFECTIONS.
We develop for patients
For 40 years we have been committed to improving patient lives. With the heritage of our successful two standard-of-care therapies for prostate & colorectal cancer, we relentlessly aspire to identify and develop innovative treatments in both oncology and bacterial infections.
Discover our pipeline from discovery to phase III in oncology and bacterial infections
Together we can establish tomorrow’s standard of care! Driven by the ambition to cure, we are always seeking partners who share the same desire to bring new innovative solutions to patients’ unmet needs. Discover our partnering opportunities
Naratuximab emtansine is a new ADC therapy for patients with B-cell malignancies working by delivering a potent cytotoxic via a novel disease target, CD37. The potential benefit observed with this potent ADC technology have brought us to the stage of actively seeking a global partner to unfold the full value of this novel therapeutic option.